Affymetrix (NASDAQ: AFFX) and Lion Biotechnologies (NASDAQ:IOVA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Profitability

This table compares Affymetrix and Lion Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affymetrix 4.24% 4.84% 2.97%
Lion Biotechnologies N/A -53.59% -51.25%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Affymetrix and Lion Biotechnologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affymetrix 0 0 0 0 N/A
Lion Biotechnologies 0 0 10 0 3.00

Lion Biotechnologies has a consensus price target of $15.31, suggesting a potential upside of 73.02%. Given Lion Biotechnologies’ higher possible upside, analysts plainly believe Lion Biotechnologies is more favorable than Affymetrix.

Institutional and Insider Ownership

65.6% of Lion Biotechnologies shares are owned by institutional investors. 13.2% of Lion Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Affymetrix and Lion Biotechnologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Affymetrix N/A N/A N/A $0.12 116.75
Lion Biotechnologies N/A N/A -$52.89 million ($1.30) -6.81

Lion Biotechnologies is trading at a lower price-to-earnings ratio than Affymetrix, indicating that it is currently the more affordable of the two stocks.

About Affymetrix

Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.